共 127 条
[1]
Smolen JS(2018)Rheumatoid arthritis Nat. Rev. Dis. Prim. 8 18001-8
[2]
Tanaka Y(2020)Rheumatoid arthritis Inflamm. Regen. 40 1-699
[3]
Smolen JS(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann. Rheum. Dis. 79 685-68
[4]
Macchi P(1995)Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) Nature 377 65-153
[5]
Johnston JA(1994)Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2 Nature 370 151-i74
[6]
Tanaka Y(2012)In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis Ann. Rheum. Dis. 71 i70-170
[7]
O’Shea JJ(2012)JAKs and STATs in immunity, immunodeficiency, and cancer N. Engl. J. Med. 368 161-ii115
[8]
O’Shea JJ(2013)Janus kinase inhibitors in autoimmune diseases Ann. Rheum. Dis. 72 ii111-i3
[9]
Kontzias A(2019)The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases? Rheumatology 58 i1-962
[10]
Yamaoka K(2019)Clinical significance of Janus kinase inhibitor selectivity Rheumatology 58 953-2020